Compare · EPIX vs LIFE
EPIX vs LIFE
Side-by-side comparison of ESSA Pharma Inc. (EPIX) and Ethos Technologies Inc. (LIFE): market cap, price performance, sector, and recent activity on the wire.
Summary
- EPIX operates in Health Care, while LIFE operates in Finance - the two are in different parts of the market.
- LIFE is the larger of the two at $2.52B, about 9.9x EPIX ($253.2M).
- LIFE has hit the wire 5 times in the past 4 weeks while EPIX has been quiet.
- LIFE has more recent analyst coverage (18 ratings vs 5 for EPIX).
- Company
- ESSA Pharma Inc.
- Ethos Technologies Inc.
- Price
- $0.20-5.01%
- $37.47-3.43%
- Market cap
- $253.2M
- $2.52B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Specialty Insurers
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2026
- News (4w)
- 0
- 5
- Recent ratings
- 5
- 18
ESSA Pharma Inc.
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company was founded in 2009 and is headquartered in Vancouver, Canada.
Ethos Technologies Inc.
aTyr Pharma, Inc., a clinical stage biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. The company's lead clinical product candidate is ATYR1923, a selective modulator of NRP2 for the treatment of patients with severe inflammatory lung diseases, including interstitial lung diseases (ILDs) and severe respiratory complications caused by COVID-19. Its product, ATYR1923, is in Phase 1b/2a multi-center clinical trial for pulmonary sarcoidosis. The company is also developing ATYR2810, a fully humanized monoclonal antibody that is in preclinical development for the treatment of various aggressive cancers. It has collaboration and license agreement with Kyorin Pharmaceutical Co., Ltd. for the development and commercialization of ATYR1923 for ILDs in Japan. The company was incorporated in 2005 and is headquartered in San Diego, California.
Latest EPIX
- SEC Form EFFECT filed by ESSA Pharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by ESSA Pharma Inc.
- SEC Form 15-12G filed by ESSA Pharma Inc.
- President and CEO Parkinson David Ross returned 65,675 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Chief Financial Officer Wood David S. returned 33,343 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Berger Franklin M returned 784,404 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Glickman Richard M returned 43,240 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Requadt Scott returned 30,002 shares to the company, closing all direct ownership in the company (SEC Form 4)
- Director Martin John Alexander returned 14,299 shares to the company, closing all direct ownership in the company (SEC Form 4)
Latest LIFE
- SEC Form 4 filed by Ethos Technologies Inc.
- SEC Form 4 filed by Ethos Technologies Inc.
- Ethos to Announce Third Quarter 2026 Financial Results on November 2, 2026
- SEC Form 8-K filed by Ethos Technologies Inc.
- Ethos Technologies downgraded by Analyst with a new price target
- CEO and Secretary Colis Peter George converted options into 70,000 shares and sold $2,695,425 worth of shares (70,000 units at $38.51) as part of a pre-agreed trading plan (SEC Form 4)
- President Wang Lingke converted options into 118,333 shares and sold $4,610,442 worth of shares (118,333 units at $38.96) as part of a pre-agreed trading plan (SEC Form 4)
- Ethos Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure
- Director Botha Roelof acquired 72,450 shares (SEC Form 4)
- Large owner Sc Us (Ttgp), Ltd. converted options into 2,371,501 shares and disposed of 2,371,501 shares (SEC Form 4)